HHS Expands Newborn Screening to Include Duchenne Muscular Dystrophy and Metachromatic Leukodystrophy

The U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr., approved on December 16 the addition of Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) to the Recommended Uniform Screening Panel (RUSP) after scientific review and public comment. According to a press release by HHS, early detection of both conditions enables children to receive FDA-approved therapies at the most effective time, helping to slow disease progression and maintain their quality of life.

According to HHS, most children with DMD or MLD are diagnosed at four to five years old, when significant muscle loss or functional decline has already taken place. Not only will adding these conditions to the RUSP help children keep their abilities longer, but it also gives families a better chance to avoid the long delays, repeated specialist visits, and financial and emotional strain that often accompany the years-long search for a diagnosis of rare diseases.

The RUSP is the list of conditions the HHS secretary recommends for universal newborn screening. States choose whether to adopt each screening, and these decisions can reshape health outcomes for millions of families. HHS’ Health Resources and Services Administration (HRSA) administers the RUSP.

“Today’s announcement represents a monumental breakthrough grounded in human compassion. As Co-Chair of the Congressional Rare Disease Caucus, I have long worked to ensure that no child suffers due to a lack of diagnosis, and expanding newborn screening is a critical part of that effort,” said Congressman Gus Bilirakis (R-FL) in a statement. “Including conditions like MLD and DMD in the newborn screening process is a major step forward. By identifying rare diseases early, we can dramatically improve a child’s chances for timely treatment, effective therapies, and, in some cases, cures.”